ASTRAZENECA PHARMA INDIA LTD.

AstraZeneca Pharma India Limited has received approval from the Central Drugs Standard Control Organization (CDSCO) to import for sale and distribution of Benralizumab 30 mg/ml solution for injection (Brand name: Fasenra®). This approval is for an additional indication: treatment of patients aged 12 years and older with Hypereosinophilic Syndrome (HES) without an identifiable non-haematologic secondary cause. The receipt of this permission allows for the marketing of Fasenra® in India for this specific indication, subject to further statutory approvals.

AstraZeneca Pharma India Ltd has announced significant appointments and a promotion within its Senior Management Personnel (SMP). Mr. Mihir Parikh has been appointed as Director - Commercial Excellence, BD & Strategy, effective August 1, 2026. Mr. Amay Ashok Pandey will join as Director – Oncology Business Unit, effective September 1, 2026. Additionally, Mr. Vinay Sharma has been promoted to Director - Rare Diseases Business Unit from his previous role as Business Unit Head - Rare Disease Business Unit, also effective August 1, 2026. These appointments and promotions are based on the recommendation of the Nomination and Remuneration Committee and approved by the Board of Directors, aligning with SEBI Listing Regulations.

AstraZeneca Pharma India Ltd announced the appointment of Mr. Praveen K Mittal as Director - Corporate Affairs, effective July 6, 2026. This appointment, approved by the Board of Directors based on the Nomination and Remuneration Committee's recommendation, fills a Senior Management Personnel position. Mr. Mittal brings nearly 30 years of experience in corporate affairs, government relations, and public policy, with a significant background in the healthcare and medical technology sectors, including leadership roles at the Export Promotion Council for Medical Devices and FICCI.

AstraZeneca Pharma India Ltd has announced the closure of its trading window for dealing in equity shares. This closure is in accordance with SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's internal code of conduct. The trading window will be shut from June 16, 2026, and will reopen 48 hours after the declaration of the un-audited financial results for the quarter ending June 30, 2026. This measure is standard practice to prevent insider trading during sensitive financial reporting periods.

AstraZeneca Pharma India Ltd has announced the resignation of two key senior management personnel: Ms. Aditi Mehta, Business Unit Director – Oncology Business Unit, and Mr. Srikanth B.S., Site Lead, India Operations. Both individuals have decided to pursue career opportunities outside the organization and will be relieved from their duties by June 12, 2026, and June 15, 2026, respectively. The company is actively seeking suitable replacements for these positions. The resignations are effective upon completion of their handover periods.

AstraZeneca Pharma India Limited has received approval from the Central Drugs Standard Control Organization (CDSCO) to import for sale and distribution of Trastuzumab deruxtecan (Enhertu®) 100 mg/5mL vial for an additional indication. This approval allows for the first-line treatment of adult patients with unresectable or metastatic HER2-positive breast cancer when used in combination with pertuzumab. The company can now proceed with marketing Enhertu® in India for this specific indication, pending any further statutory approvals.

AstraZeneca Pharma India Ltd has received an appeal order from the Deputy Commissioner of State Tax (Appeal) concerning the financial year 2018-19. The order upholds adjustments made by the Assistant Commissioner of State Tax Investigation related to supplies under the Patient Access Program. The company plans to challenge this order before the GST Appellate Tribunal (GSTAT). The disputed amount is approximately ₹9.24 crores, excluding interest and penalty, with the overall financial implication not yet determinable.

AstraZeneca Pharma India Ltd has announced the surrender of its factory license to the Department of Factories, Boilers, Industrial Safety and Health for cancellation. The license was valid until December 31, 2026. This action follows previous intimations regarding the exit from the manufacturing site and the surrender of the manufacturing license. The company has provided details as required by SEBI regulations.

AstraZeneca Pharma India Ltd announced the resignations of Mr. Ayush Kumar Agarwal, Business Unit Director, and Ms. Shikha Mirchandani Chatrath, Director, effective June 12, 2026, and August 3, 2026, respectively. Both are pursuing career opportunities outside the company. The company is seeking suitable replacements and has provided details as per SEBI regulations.

AstraZeneca Pharma India Limited announced its FY26 results, reporting a 33% year-on-year growth in total revenue, reaching ₹22,755.8 Mn. The company saw growth in Oncology and Biopharmaceuticals, with 11 new regulatory approvals for medicines and indications. Key approvals include Durvalumab for endometrial and muscle-invasive bladder cancer, Eculizumab for rare diseases, and Osimertinib for NSCLC. The company focuses on delivering innovative medicines and addressing unmet patient needs in India.